Pam3CSK4

• Description :

  Pam3CSK4 is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2[1].

• Product Name Alternative :

  Pam3Cys-Ser- (Lys) 4

• UNSPSC :

  12352209

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Toll-like Receptor (TLR)

• Type :

  Peptides

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/pam3csk4.html

• Solubility :

  H2O

• Smiles :

  CCCCCCCCCCCCCCCC(OCC(OC(CCCCCCCCCCCCCCC)=O)CSC[C@H](NC(CCCCCCCCCCCCCCC)=O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)=O

• Molecular Formula :

  C81H156N10O13S

• Molecular Weight :

  1510.23

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  Staphylococcus aureus

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported

• Isoform :

  TLR1; TLR2

• Citation 01 :

  Antiviral Res. 2022 Jul:203:105346.|Biochem Biophys Res Commun. 2024 Apr 16:704:149661.|Int Immunopharmacol. 2022 May:106:108613.|Microbes Infect. 2024 Jan-Feb;26 (1-2) :105244.|Mol Immunol. 2021 Feb;130:85-95.|Sci Rep. 2023 Nov 9;13 (1) :19440.|Chin Herb Med. 2024 Apr 30;16 (3) :422-434.|Int Immunopharmacol. 2022 Dec;113 (Pt A) :109312.|J Pharm Anal. 2025 Jan;15 (1) :101054.|Nat Immunol. 2025 Oct;26 (10) :1660-1672.|Phytomedicine. 2025 Jun:141:156705.|PLoS Pathog. 2024 Nov 5;20 (11) :e1012614.|Sci China Life Sci. 2024 Dec;67 (12) :2664-2677.|Sci Rep. 2022 Oct 12;12 (1) :17058.

• CAS Number :

  [112208-00-1]